Brent J, McMartin K, Phillips S, Burkhart K K, Donovan J W, Wells M, Kulig K
Toxicology Associates, Section of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver 80210, USA.
N Engl J Med. 1999 Mar 18;340(11):832-8. doi: 10.1056/NEJM199903183401102.
Ethylene glycol poisoning causes metabolic acidosis and renal failure and may cause death. The standard treatment is inhibition of alcohol dehydrogenase with ethanol, given in intoxicating doses, and adjunctive hemodialysis. We studied the efficacy of fomepizole, a new inhibitor of alcohol dehydrogenase, in the treatment of ethylene glycol poisoning.
We administered intravenous fomepizole to 19 patients with ethylene glycol poisoning (plasma ethylene glycol concentration, > or =20 mg per deciliter [3.2 mmol per liter]). Patients who met specific criteria also underwent hemodialysis. Treatment was continued until plasma ethylene glycol concentrations were less than 20 mg per deciliter. Acid-base status, renal function, the kinetics of fomepizole, and ethylene glycol metabolism were assessed at predetermined intervals.
Fifteen of the patients initially had acidosis (mean serum bicarbonate concentration, 12.9 mmol per liter). Acid-base status tended to normalize within hours after the initiation of treatment with fomepizole. One patient with extreme acidosis died. In nine patients, renal function decreased during therapy; at enrollment, all nine had high serum creatinine concentrations and markedly elevated plasma glycolate concentrations (> or =97.7 mg per deciliter [12.9 mmol per liter]). None of the 10 patients with normal serum creatinine concentrations at enrollment had renal injury during treatment; all 10 had plasma glycolate concentrations at or below 76.8 mg per deciliter (10.1 mmol per liter). Renal injury was independent of the initial plasma ethylene glycol concentration. The plasma concentration of glycolate and the urinary excretion of oxalate, the major metabolites of ethylene glycol, uniformly fell after the initiation of fomepizole therapy. Few adverse effects were attributable to fomepizole.
In patients with ethylene glycol poisoning, fomepizole administered early in the course of intoxication prevents renal injury by inhibiting the formation of toxic metabolites.
乙二醇中毒可导致代谢性酸中毒和肾衰竭,并可能致死。标准治疗方法是给予中毒剂量的乙醇以抑制乙醇脱氢酶,并辅助进行血液透析。我们研究了新型乙醇脱氢酶抑制剂甲吡唑治疗乙二醇中毒的疗效。
我们对19例乙二醇中毒患者(血浆乙二醇浓度≥20mg/分升[3.2mmol/升])静脉注射甲吡唑。符合特定标准的患者也接受血液透析。治疗持续至血浆乙二醇浓度低于20mg/分升。在预定时间间隔评估酸碱状态、肾功能、甲吡唑的动力学以及乙二醇代谢情况。
15例患者最初存在酸中毒(平均血清碳酸氢盐浓度为12.9mmol/升)。在用甲吡唑治疗开始后的数小时内,酸碱状态趋于正常。1例极度酸中毒患者死亡。9例患者在治疗期间肾功能下降;入组时,这9例患者的血清肌酐浓度均较高,血浆乙醇酸盐浓度显著升高(≥97.7mg/分升[12.9mmol/升])。入组时血清肌酐浓度正常的10例患者在治疗期间均未发生肾损伤;这10例患者的血浆乙醇酸盐浓度均在76.8mg/分升(10.1mmol/升)或以下。肾损伤与初始血浆乙二醇浓度无关。甲吡唑治疗开始后,乙二醇的主要代谢产物乙醇酸盐的血浆浓度和草酸盐的尿排泄量均一致下降。很少有不良反应归因于甲吡唑。
在乙二醇中毒患者中,在中毒过程早期给予甲吡唑可通过抑制有毒代谢产物的形成来预防肾损伤。